2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Venture funding drops again, but there’s no need to panic yet.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.